Needham Reiterates Buy on Cartesian Therapeutics, Maintains $41 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a price target of $41.
October 16, 2024 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Cartesian Therapeutics and maintained a $41 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $41 price target by a reputable analyst suggests a positive outlook for Cartesian Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100